Literature DB >> 3172339

Negative regulation of retrovirus expression in embryonal carcinoma cells mediated by an intragenic domain.

T P Loh1, L L Sievert, R W Scott.   

Abstract

An intragenic region spanning the tRNA primer binding site of a Moloney murine leukemia virus recombinant retrovirus was found to restrict expression specifically in embryonal carcinoma (EC) cells. When the inhibitory domain was present, the levels of steady-state RNA synthesized from integrated recombinant templates in stable cotransformation assays were reduced 20-fold in EC cells but not in C2 myoblast cells. Transient-cotransfection assays showed that repression of a template containing the EC-specific inhibitory component was relieved by an excess of specific competitor DNA. In addition, repression mediated by the inhibitory component was orientation independent. This evidence demonstrates the presence of a saturable, trans-acting negative regulatory factor(s) in EC cells and suggests that the interaction of the factor(s) with the intragenic inhibitory component occurs at the DNA level.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3172339      PMCID: PMC253839     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  45 in total

1.  DNA sequence changes of mutations altering attenuation control of the histidine operon of Salmonella typhimurium.

Authors:  H M Johnston; J R Roth
Journal:  J Mol Biol       Date:  1981-02-05       Impact factor: 5.469

2.  Tissue-specific activation of a cloned alpha-fetoprotein gene during differentiation of a transfected embryonal carcinoma cell line.

Authors:  R W Scott; T F Vogt; M E Croke; S M Tilghman
Journal:  Nature       Date:  1984 Aug 16-22       Impact factor: 49.962

3.  Independent mechanisms involved in suppression of the Moloney leukemia virus genome during differentiation of murine teratocarcinoma cells.

Authors:  O Niwa; Y Yokota; H Ishida; T Sugahara
Journal:  Cell       Date:  1983-04       Impact factor: 41.582

4.  Delayed de novo methylation in teratocarcinoma suggests additional tissue-specific mechanisms for controlling gene expression.

Authors:  J W Gautsch; M C Wilson
Journal:  Nature       Date:  1983-01-06       Impact factor: 49.962

5.  Transformation of mammalian cells to antibiotic resistance with a bacterial gene under control of the SV40 early region promoter.

Authors:  P J Southern; P Berg
Journal:  J Mol Appl Genet       Date:  1982

6.  Non-function of a Moloney murine leukaemia virus regulatory sequence in F9 embryonal carcinoma cells.

Authors:  E Linney; B Davis; J Overhauser; E Chao; H Fan
Journal:  Nature       Date:  1984 Mar 29-Apr 4       Impact factor: 49.962

7.  De novo methylation, expression, and infectivity of retroviral genomes introduced into embryonal carcinoma cells.

Authors:  C L Stewart; H Stuhlmann; D Jähner; R Jaenisch
Journal:  Proc Natl Acad Sci U S A       Date:  1982-07       Impact factor: 11.205

8.  Purification of biologically active globin messenger RNA by chromatography on oligothymidylic acid-cellulose.

Authors:  H Aviv; P Leder
Journal:  Proc Natl Acad Sci U S A       Date:  1972-06       Impact factor: 11.205

9.  Physical and biological features of polyoma virus mutants able to infect embryonal carcinoma cell lines.

Authors:  M Vasseur; M Katinka; P Herbomel; M Yaniv; D Blangy
Journal:  J Virol       Date:  1982-09       Impact factor: 5.103

10.  Infectivity and methylation of retroviral genomes is correlated with expression in the animal.

Authors:  H Stuhlmann; D Jähner; R Jaenisch
Journal:  Cell       Date:  1981-10       Impact factor: 41.582

View more
  18 in total

1.  Lack of shielding of primer binding site silencer-mediated repression of an internal promoter in a retrovirus vector by the putative insulators scs, BEAD-1, and HS4.

Authors:  C Modin; F S Pedersen; M Duch
Journal:  J Virol       Date:  2000-12       Impact factor: 5.103

2.  Transcription factor binding sites downstream of the human immunodeficiency virus type 1 transcription start site are important for virus infectivity.

Authors:  C Van Lint; C A Amella; S Emiliani; M John; T Jie; E Verdin
Journal:  J Virol       Date:  1997-08       Impact factor: 5.103

Review 3.  Host restriction factors blocking retroviral replication.

Authors:  Daniel Wolf; Stephen P Goff
Journal:  Annu Rev Genet       Date:  2008       Impact factor: 16.830

4.  Determinants of retrovirus gene expression in embryonal carcinoma cells.

Authors:  E Akgün; M Ziegler; M Grez
Journal:  J Virol       Date:  1991-01       Impact factor: 5.103

5.  Transfer of single gene-containing long terminal repeats into the genome of mammalian cells by a retroviral vector carrying the cre gene and the loxP site.

Authors:  A Choulika; V Guyot; J F Nicolas
Journal:  J Virol       Date:  1996-03       Impact factor: 5.103

6.  Differential control of retrovirus silencing in embryonic cells by proteasomal regulation of the ZFP809 retroviral repressor.

Authors:  Cheng Wang; Stephen P Goff
Journal:  Proc Natl Acad Sci U S A       Date:  2017-01-23       Impact factor: 11.205

7.  cis-acting elements that mediate the negative regulation of Moloney murine leukemia virus in mouse early embryos.

Authors:  M Vernet; J Cebrian
Journal:  J Virol       Date:  1996-08       Impact factor: 5.103

8.  The Moloney murine leukemia virus repressor binding site represses expression in murine and human hematopoietic stem cells.

Authors:  Dennis L Haas; Carolyn Lutzko; Aaron C Logan; Gerald J Cho; Dianne Skelton; Xiao Jin Yu; Karen A Pepper; Donald B Kohn
Journal:  J Virol       Date:  2003-09       Impact factor: 5.103

9.  DNase I-hypersensitive sites are associated with both long terminal repeats and with the intragenic enhancer of integrated human immunodeficiency virus type 1.

Authors:  E Verdin
Journal:  J Virol       Date:  1991-12       Impact factor: 5.103

10.  A single point mutation activates the Moloney murine leukemia virus long terminal repeat in embryonal stem cells.

Authors:  M Grez; M Zörnig; J Nowock; M Ziegler
Journal:  J Virol       Date:  1991-09       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.